Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series.

Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several small studies and case reports that provide evidence for the potential use of biologic therapies in the treatment of erythrodermic psoriasis. This case series suggests that risankizumab may represent an effective and sustainable treatment option for patients with a history of EP.